SCHEMBL6372123

SCHEMBL6372123

O=C1Nc2cc(Cl)ccc2C1c1ncnc2cc(OCCCN3CCOCC3)ccc12

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.78
KDR P35968 3/20 0.47
EGFR P00533 3/20 0.47
BRAF P15056 2/20 0.47
SRC P12931 1/20 0.46
SIGMAR1 Q99720 3/20 0.46
AURKA O14965 2/20 0.44
AURKB Q96GD4 2/20 0.44
ACHE P22303 1/20 0.42
EPHX2 P34913 2/20 0.42
TNNI3K Q59H18 1/20 0.42
AVPR1B P47901 3/20 0.42
FLT3 P36888 1/20 0.42
PSEN1 P49768 1/20 0.42
PSEN2 P49810 1/20 0.42
APH1B Q8WW43 1/20 0.42
NCSTN Q92542 1/20 0.42
APH1A Q96BI3 1/20 0.42
PSENEN Q9NZ42 1/20 0.42
LRRK2 Q5S007 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4504657 0.99 CHEK1 (0.77) CHEK1KDREGFRBRAFSRC
SCHEMBL4510546 0.90 CHEK1 (0.78) CHEK1KDREGFRBRAFSRC
Hydrochloric Acid SCHEMBL4518548 0.89 CHEK1 (0.77) CHEK1KDREGFRBRAFSRC
SCHEMBL7206444 0.89 CHEK1 (0.77) CHEK1KDREGFRBRAFSRC
SCHEMBL7205685 0.88 CHEK1 (0.75) CHEK1KDREGFRBRAFSRC
SCHEMBL7210129 0.88 CHEK1 (0.75) CHEK1KDREGFRBRAFSRC
SCHEMBL7211233 0.88 CHEK1 (1.00) CHEK1KDREGFRBRAFSRC
SCHEMBL5278912 0.86 CHEK1 (0.68) CHEK1KDREGFRBRAFSRC
Hydrochloric Acid SCHEMBL5499642 0.85 CHEK1 (0.67) CHEK1KDREGFRBRAFSRC
Hydrochloric Acid SCHEMBL5499449 0.85 CHEK1 (0.71) CHEK1KDREGFRBRAFSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050070559-A1 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 ASTRAZENECA AB (SE) 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070559-A1 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 GSK3A, GSK3B, PYGB CHEK1 881/4885KDR 3980/4885EGFR 2648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.